Genetic heterogeneity in HER2 testing may influence therapy eligibility

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 161-168

  Bernasconi, Barbara ^a   Chiaravalli, Anna Maria ^a   Finzi, Giovanna ^a   Milani, Katia ^a   Tibiletti, Maria Grazia ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Breast cancers; Genetic heterogeneity; HER2 amplification; Therapy eligibility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL POPULATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; TISSUE SECTION;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASMS, HORMONE-DEPENDENT; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2;

EID: 84860336925     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1744-3     Document Type: Article

References (26)

1. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Allred RJ Cote M Dowsett PL Fitzgibbons WM Hanna A Langer LM McShane S Paik MD Pegram EA Perez MF Press A Rhodes C Sturgeon SE Taube R Tubbs GH Vance M van de Vijver TM Wheeler DF Hayes 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
2. H Joensuu PL Kellokumpu-Lehtinen P Bono T Alanko V Kataja R Asola T Utriainen R Kokko A Hemminki M Tarkkanen T Turpeenniemi-Hujanen S Jyrkkio M Flander L Helle S Ingalsuo K Johansson AS Jaaskelainen M Pajunen M Rauhala J Kaleva-Kerola T Salminen M Leinonen I Elomaa J Isola 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 8 809 820 16495393 10.1056/NEJMoa053028 1:CAS:528:DC%2BD28Xhsl2gsrY%3D (Pubitemid 43290919)
3. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
4. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
5. A Di Leo HL Gomez Z Aziz Z Zvirbule J Bines MC Arbushites SF Guerrera M Koehler C Oliva SH Stein LS Williams J Dering RS Finn MF Press 2008 Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J Clin Oncol 26 34 5544 5552 18955454 10.1200/JCO.2008.16.2578 1:CAS:528: DC%2BD1MXmsVSktA%3D%3D
6. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski A Jagiello-Gruszfeld J Crown A Chan B Kaufman D Skarlos M Campone N Davidson M Berger C Oliva SD Rubin S Stein D Cameron 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 26 2733 2743 17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D (Pubitemid 46021510)
7. MG Tibiletti V Martin B Bernasconi B Del Curto L Pecciarini S Uccella G Pruneri M Ponzoni L Mazzucchelli G Martinelli AJ Ferreri G Pinotti A Assanelli M Scandurra C Doglioni E Zucca C Capella F Bertoni 2009 BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome Hum Pathol 40 5 645 652 19144384 10.1016/j.humpath.2008.06.032 1:CAS:528:DC%2BD1MXktl2isrs%3D
8. Interphase FISH on solid tumors: recommendations for use on histological sections in daily practice. http://sigu.net/
9. ISCN: An International System for Human Cytogenetic Nomenclature (2009) In: Shaffer LG, Slovak ML, Campbell LJ (eds) S. Karger, Basel
10. GH Vance TS Barry KJ Bloom PL Fitzgibbons DG Hicks RB Jenkins DL Persons RR Tubbs ME Hammond 2009 Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines Arch Pathol Lab Med 133 4 611 612 19391661
11. MG Tibiletti 2004 Specificity of interphase fluorescence in situ hybridization for detection of chromosome aberrations in tumor pathology Cancer Genet Cytogenet 155 2 143 148 15571800 10.1016/j.cancergencyto.2004.03.005 1:CAS:528:DC%2BD2cXhtVantrbO (Pubitemid 39574924)
12. SF Paternoster SR Brockman RF McClure ED Remstein PJ Kurtin GW Dewald 2002 A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization Am J Pathol 160 6 1967 1972 12057901 10.1016/S0002-9440(10)61146-7 1:CAS:528:DC%2BD38XltFOrsro%3D (Pubitemid 34663389)
13. G Jonsson J Staaf J Vallon-Christersson M Ringner K Holm C Hegardt H Gunnarsson R Fagerholm C Strand BA Agnarsson O Kilpivaara L Luts P Heikkila K Aittomaki C Blomqvist N Loman P Malmstrom H Olsson OT Johannsson A Arason H Nevanlinna RB Barkardottir A Borg 2010 Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics Breast Cancer Res 12 3 R42 10.1186/bcr2596 20576095 10.1186/bcr2596
14. F Sircoulomb I Bekhouche P Finetti J Adelaide A Ben Hamida J Bonansea S Raynaud C Innocenti E Charafe-Jauffret C Tarpin F Ben Ayed P Viens J Jacquemier F Bertucci D Birnbaum M Chaffanet 2010 Genome profiling of ERBB2-amplified breast cancers BMC Cancer 10 539 10.1186/1471-2407-10-539 20932292 10.1186/1471-2407-10-539
15. J Staaf G Jonsson M Ringner J Vallon-Christersson D Grabau A Arason H Gunnarsson BA Agnarsson PO Malmstrom OT Johannsson N Loman RB Barkardottir A Borg 2010 High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer Breast Cancer Res 12 3 25 10.1186/bcr2568 10.1186/bcr2568
16. MG Tibiletti 2007 Interphase FISH as a new tool in tumor pathology Cytogenet Genome Res 118 2-4 229 236 18000375 10.1159/000108305 1:CAS:528:DC%2BD2sXht12ktLbK (Pubitemid 350125261)
17. C Lengauer KW Kinzler B Vogelstein 1997 DNA methylation and genetic instability in colorectal cancer cells Proc Natl Acad Sci USA 94 6 2545 2550 9122232 10.1073/pnas.94.6.2545 1:CAS:528:DyaK2sXhvF2ksLw%3D (Pubitemid 27136912)
18. M Smid M Hoes AM Sieuwerts S Sleijfer Y Zhang Y Wang JA Foekens JW Martens 2011 Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes Breast Cancer Res Treat 128 1 23 30 20632083 10.1007/s10549-010-1026-5 1:CAS:528:DC%2BC3MXnsVWmurc%3D
19. M Brunelli E Manfrin G Martignoni K Miller A Remo D Reghellin S Bersani S Gobbo A Eccher M Chilosi F Bonetti 2009 Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria Am J Clin Pathol 131 5 678 682 19369627 10.1309/AJCP09VUTZWZXBMJ
20. LP Pertschuk CA Axiotis JG Feldman YD Kim SJ Karavattayhayyil L Braithwaite 1999 Marked intratumoral heterogeneity of the proto-oncogene her-2/neu determined by three different detection systems Breast J 5 6 369 374 11348316 10.1046/j.1524-4741.1999.97088.x
21. SS Shah RP Ketterling MP Goetz JN Ingle CA Reynolds EA Perez B Chen 2010 Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer Hum Pathol 41 1 103 106 19762065 10.1016/j.humpath.2009.07.001 1:CAS:528:DC%2BD1MXhsFaisrfK
22. SJ Shin E Hyjek E Early DM Knowles 2006 Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in situ hybridization and tissue microarray Int J Surg Pathol 14 4 279 284 17041191 10.1177/1066896906293055 (Pubitemid 44545764)
23. JT Lewis RP Ketterling KC Halling C Reynolds RB Jenkins DW Visscher 2005 Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining Am J Clin Pathol 124 2 273 281 16040300 10.1309/J9VXABUGKC4Y07DL (Pubitemid 41060140)
24. A Santinelli E Pisa D Stramazzotti G Fabris 2008 HER-2 status discrepancy between primary breast cancer and metastatic sites Impact on target therapy Int J Cancer 122 5 999 1004 17973263 10.1002/ijc.23051 1:CAS:528: DC%2BD1cXhslGhtb0%3D (Pubitemid 351213996)
25. C Tapia S Savic U Wagner R Schonegg H Novotny B Grilli M Herzog AD Barascud I Zlobec G Cathomas L Terracciano G Feichter L Bubendorf 2007 HER2 gene status in primary breast cancers and matched distant metastases Breast Cancer Res 9 3 R31 17511881 10.1186/bcr1676 (Pubitemid 350215176)
26. CY Hsu AF Li CF Yang DM Ho 2010 Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer Arch Pathol Lab Med 134 2 162 20121596 author reply 163